Liver transplantation has been the main standard treatment for many liver diseases in the final stages. Lately, long-term graft and patient survival are common after transplantation, however, the recipient must be subjected to immunosuppression, which prevents a good quality of life and can reduce survival by promoting the development of cancer or increasing the risk of infection, cardiovascular diseases and kidney failure. Therefore, there is a need to promote protocols after transplantation.
It has been shown that mesenchymal stem cells have an anti-inflammatory and immunoregulatory potential, which suggests that these cells could be of interest in the transplantation of solid organs.
Detry O, Vandermeulen M, Delbouille MH, Somja J, Bletard N, Briquet A, Lechanteur C, Giet O, Baudoux E, Hannon M, Baron F, Beguin Y., Infusion of mesenchymal cells after liver transplantation: an open clinical study of phase I-II, Journal of Hepatology, 2016-2017.